Edgewise Therapeutics, Inc. cotiza a 36.28 USD y tiene una capitalización bursátil de $3.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies i…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.53 | $-0.46 | $-0.47 |
| Estimado | $-0.56 | $-0.47 | $-0.48 | $-0.44 |
| Sorpresa | — | -12.8% | +4.2% | -6.8% |
| Métrica | EWTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -32.1% | -40.4% | +8.3% |
| ROA | -30.4% | -32.0% | +1.6% |
| Current Ratio | 19.85 | 2.84 | +17.01 |
| Debt / Equity | — | 0.28 | — |